TABLE 7.
Country, yr | Reference | Prevalence of primary resistance (% [no. with resistance/total no.]) | MIC breakpoint (μg/ml) | No., type of strains tested for gyrA mutation | No. (%) of strains with: |
|||
---|---|---|---|---|---|---|---|---|
Mutationa |
No mutation detected | |||||||
N87 | D91 | Other | ||||||
Taiwan, 2010 | Present study | 5.8 (18/312) | >1 | 18, resistant | 8 (44.4) | 8 (44.4) | 0 | 2 (11.1) |
287, susceptible | 3 (1) | 1 (0.35) | 1 (0.35) | 282 (98.3) | ||||
Southern Taiwan, 2009 | 15 | 5.7 (12/210) | >1 | 12, resistant | 4 (33.3) | 8 (66.7) | 3 (25) | 0 |
Hong Kong, 2008 | 19 | 11.5 (22/191) | >1 | 22, resistant | 6 (27.3) | 10 (45.5) | 1 (4.5) | 5 (22.7) |
Korea, 2005 | 17 | 10.4 (14/135) | >1 | 14, resistant | 0 | 14 (100) | 0 | 0 |
Belgium, 2006 | 1 | 16.8 (82/488) | >1 | 70, resistant | 40 (57.1) | 33 47.1) | N/A | 0 |
Slovenia, 2009 | 16 | 8.3 (33/397) | >1 (?)b | 33, resistant | 12 (36.4) | 19 (57.6) | ||
Japan, 2006 | 25 | 15 (76/507) | ≥1 | 70, resistant | 50 (71.4) | 18 (25.7) | 5 (7.1) | 2 (2.9) |
50, susceptible | 3 (6) | 4 (8) | 0 | 43 (86) | ||||
United Kingdom, 2009 | 5 | 7.5 (19/255) (ciprofloxacin) | ≥1 | 18, resistant | 4 (22.2) | 12 (67) | 1 (5.6) | 1 |
32, susceptible | 3 (9) | 0 | 0 | 29 (91) | ||||
France, 2007 | 3 | 17.2 (22/128) | >1 | 22, resistant | 10 (45.5) | 12 (54.5) | 1 (4.5) | 0 |
106, susceptible | 18 (17) | 0 | 0 | 88 (83) |
N87, point mutation at codon 87 of the gyrA gene; D91, point mutation at codon 91 of the gyrA gene; N/A, not available.
?, the MIC breakpoint is not mentioned in that study.